Aaron Y. Mochizuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aaron Y. Mochizuki has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Robert M. Prins
University of California, Los Angeles 2 Los Angeles, CA
27 shared publications - April Bell
Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois
21 shared publications Bin Zhang
21 shared publicationsChangyou Zhou
21 shared publicationsCraig Horbinski
21 shared publications- David H. Munn
Georgia Cancer Center, Augusta University, Augusta, Georgia
21 shared publications
Latest Publications
- 17 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype-specific phenotypes
Background: Oligodendroglioma is a primary central nervous system tumor classified by the presence of isocitrate dehydrogenase (IDH) mutations and codeletion of 1p/19q. A lack of faithful preclinical model systems for this disease has limited progress in understanding the biology of this genetically unique subtype of adult diffuse-type glioma and in developing new effective therapies. To address this unmet need, we sought to establish a mouse model that faithfully recapitulates the genetic and phenotypic features of human IDH-mutant 1p/19q-codeleted oligodendroglioma. Methods: We performed in utero electroporation to introduce distinct combinations of genetic alterations and evaluated their potential to form tumors. Resulting tumors were characterized by histology, metabolite profiling, RNA-sequencing and single-cell RNA-sequencing. Results: We identified co-expression of IDH1R132H and PIK3CAE545K together with loss of Cic, Fubp1, and Cdkn2a (termed OligoCdkn2a) as the optimal genetic combination to drive fully penetrant tumors that histologically resemble human grade III IDH-mutant 1p/19q-codeleted oligodendroglioma. Substituting Cdkn2a loss with Trp53 deletion decreased latency and shifted tumors toward high-grade astrocytoma histology. OligoCdkn2a tumors displayed metabolic and transcriptional changes associated with IDH and CIC mutations, and single-cell sequencing identified a bias toward oligodendrocyte differentiation compared to an IDH wild-type glioblastoma mouse model. Conclusions: To our knowledge, OligoCdkn2a tumors represent the first autochthonous, genetically engineered mouse model to recapitulate the genetic, histological, and transcriptional features of human IDH-mutant 1p/19q-codeleted oligodendrogliomas. This model will provide a valuable platform to further dissect mechanisms of tumorigenesis and test novel therapeutic strategies for this molecularly distinct glioma subtype.
- 17 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype-specific phenotypes
Background: Oligodendroglioma is a primary central nervous system tumor classified by the presence of isocitrate dehydrogenase (IDH) mutations and codeletion of 1p/19q. A lack of faithful preclinical model systems for this disease has limited progress in understanding the biology of this genetically unique subtype of adult diffuse-type glioma and in developing new effective therapies. To address this unmet need, we sought to establish a mouse model that faithfully recapitulates the genetic and phenotypic features of human IDH-mutant 1p/19q-codeleted oligodendroglioma. Methods: We performed in utero electroporation to introduce distinct combinations of genetic alterations and evaluated their potential to form tumors. Resulting tumors were characterized by histology, metabolite profiling, RNA-sequencing and single-cell RNA-sequencing. Results: We identified co-expression of IDH1R132H and PIK3CAE545K together with loss of Cic, Fubp1, and Cdkn2a (termed OligoCdkn2a) as the optimal genetic combination to drive fully penetrant tumors that histologically resemble human grade III IDH-mutant 1p/19q-codeleted oligodendroglioma. Substituting Cdkn2a loss with Trp53 deletion decreased latency and shifted tumors toward high-grade astrocytoma histology. OligoCdkn2a tumors displayed metabolic and transcriptional changes associated with IDH and CIC mutations, and single-cell sequencing identified a bias toward oligodendrocyte differentiation compared to an IDH wild-type glioblastoma mouse model. Conclusions: To our knowledge, OligoCdkn2a tumors represent the first autochthonous, genetically engineered mouse model to recapitulate the genetic, histological, and transcriptional features of human IDH-mutant 1p/19q-codeleted oligodendrogliomas. This model will provide a valuable platform to further dissect mechanisms of tumorigenesis and test novel therapeutic strategies for this molecularly distinct glioma subtype.
- Open Access
- 17 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3792-3800
Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma
Antiseizure medications, such as levetiracetam, are commonly used in glioma patients. Retrospective analyses evaluating effects of antiseizure medications on glioma patient survival have yielded inconsistent results, probably due to confounding factors of glioma subtype and drug class. Here we present retrospective real-world clinical data that demonstrate longer overall survival for children with diffuse midline glioma (DMG) who were taking levetiracetam, which was not evident in pediatric patients with hemispheric high-grade glioma. In preclinical models, levetiracetam reduces glioma proliferation and tumor burden, extending survival of mice bearing DMG orthotopic xenografts. These beneficial effects were not found in hemispheric high-grade glioma patient-derived orthotopic xenograft models. The subtype-specificity of this antiproliferative effect of levetiracetam is congruent with recent findings that GABAergic neuron-to-glioma synapses promote glioma growth in DMG but not hemispheric high-grade glioma. We demonstrate here that levetiracetam attenuates low-frequency GABAergic synaptic transmission in a glioma-specific manner, reducing GABAergic synaptic currents in DMG but not in healthy neurons. This effect is independent of action on SV2A, the chief mechanism by which levetiracetam functions to prevent and treat seizures. Taken together, these findings indicate a promising approach to target GABAergic synapses in DMG and suggest that use of levetiracetam in DMG should be further studied in future prospective clinical studies.
- 17 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3792-3800
Open AccessLevetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma
Antiseizure medications, such as levetiracetam, are commonly used in glioma patients. Retrospective analyses evaluating effects of antiseizure medications on glioma patient survival have yielded inconsistent results, probably due to confounding factors of glioma subtype and drug class. Here we present retrospective real-world clinical data that demonstrate longer overall survival for children with diffuse midline glioma (DMG) who were taking levetiracetam, which was not evident in pediatric patients with hemispheric high-grade glioma. In preclinical models, levetiracetam reduces glioma proliferation and tumor burden, extending survival of mice bearing DMG orthotopic xenografts. These beneficial effects were not found in hemispheric high-grade glioma patient-derived orthotopic xenograft models. The subtype-specificity of this antiproliferative effect of levetiracetam is congruent with recent findings that GABAergic neuron-to-glioma synapses promote glioma growth in DMG but not hemispheric high-grade glioma. We demonstrate here that levetiracetam attenuates low-frequency GABAergic synaptic transmission in a glioma-specific manner, reducing GABAergic synaptic currents in DMG but not in healthy neurons. This effect is independent of action on SV2A, the chief mechanism by which levetiracetam functions to prevent and treat seizures. Taken together, these findings indicate a promising approach to target GABAergic synapses in DMG and suggest that use of levetiracetam in DMG should be further studied in future prospective clinical studies.
- Open Access
- 6 August 2026
- Published by Wiley in Brain Pathology
- p. e70132
A frontal lobe mass in a 6‐year‐old girl
- 6 August 2026
- Published by Wiley in Brain Pathology
- p. e70132
Open AccessA frontal lobe mass in a 6‐year‐old girl
- 16 July 2026
- Published by Elsevier in Cancer Genetics
- Vol. 306-307, 232-236
Discordant neoplasms in monozygotic twins with a germline RECQL5 variant
- 16 July 2026
- Published by Elsevier in Cancer Genetics
- Vol. 306-307, 232-236
Discordant neoplasms in monozygotic twins with a germline RECQL5 variant
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplementary Materials and Methods
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplementary Materials and Methods
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 1. Inclusion and exclusion criteria for the analysis of human subjects diagnosed with glioblastoma (GBM).
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 1. Inclusion and exclusion criteria for the analysis of human subjects diagnosed with glioblastoma (GBM).
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 5. Confirmation of gut microbiota depletion.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 5. Confirmation of gut microbiota depletion.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 4. Confirmatory analysis of T cell depletion method.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 4. Confirmatory analysis of T cell depletion method.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 6. Characterization of the potent clinical-grade IDO enzyme inhibitor, BGB-7204.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 6. Characterization of the potent clinical-grade IDO enzyme inhibitor, BGB-7204.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 2. Glioblastoma patient overall survival.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Supplemental Figure 2. Glioblastoma patient overall survival.